Tjoapack has doubled its packaging capacity with the completion of its Netherlands facility expansion.
Tjoapack, a global pharmaceutical contract packaging organization, announced on April 13, 2022 that the expansion of its Etten-Leur facility in the Netherlands has been completed. The expansion follows an over €10 million investment into the facility. This is the company’s first investment since its acquisition of Pharma Packaging Solutions, a US healthcare packaging firm.
Tjoapack, which specializes in primary and secondary packaging of oral solids and injectables, has doubled its packaging capacity through the investment. The expansion includes the addition of 10 new production rooms and a total size increase of the facility from 8400m2 to 11,500m2. The expansion also includes three new production lines, a fully automated packaging line for vials, and two new high-speed production lines for oral solids. The facility now has a total of 18 packaging lines for blisters, vials, and bottles, with the capacity of packaging 12 million vials per year and 500 blisters per minute.
The company has also invested in increasing its warehousing and cold chain capabilities, as well as further increasing packaging capacity by the end of the year through purchasing more blister machines and a new packaging line for pre-filled syringes.
“Packaging is of course fundamental to the safe, effective delivery of virtually every pharmaceutical product,” said Boy Tjoa, managing director of Tjoapack, in a press release. “I am proud that through our expansion we can help bring even more products to market safely. We remain committed to our European headquarters and this latest investment is an important step to meeting the growing needs of our customers and assure healthcare products are usable, available, traceable, and affordable.”
Source: Tjoapack
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.